Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia
Status:
Withdrawn
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and
efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed
and refractory acute B lymphoblastic leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University